GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GFH-018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GFH-018 overview
GF-101 is under development for the treatment of metastatic solid tumors including hepatocellular carcinoma (HCC), cholangiocarcinoma, gallbladder cancer, pancreatic cancer, colorectal cancer, urothelium carcinoma, cervical cancer, head and neck squamous cell carcinoma, esophageal cancer, nasopharyngeal carcinoma, non-small cell lung carcinoma. It is administered through oral route in the form of tablet. The drug candidate acts by targeting TGF beta receptor type 1 (TGFBR1).
The drug candidate was under development for the treatment of hepatocellular carcinoma.
GenFleet Therapeutics (Shanghai) overview
GenFleet Therapeutics (Shanghai) (GenFleet Therapeutics) is a clinical-stage biotechnology company that focuses on cutting-edge oncology and immunology therapies. The company’s pipeline products include GFH018, a PD-1 inhibitor that treats patients with advanced solid tumors; GFH925 for advanced solid tumors and non-small cell lung cancer; GFH312 targets autoimmune diseases and peripheral arterial disease; GFH009 treats adult acute myeloid leukemia and peripheral T cell lymphoma; GFS101A for solid tumors; GFH647 targets hematological malignancies; GFH220 treats hematological malignancies and solid tumors. Its GF-1015 and GF-2010 target solid tumors. It works in partnership with Innovent Biologics Inc and Merck KGaA, among others. GenFleet Therapeutics is headquartered in Shanghai, China.
For a complete picture of GFH-018’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
